ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Nashville, TN, USA:

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO)

of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....

Enrolling
Hodgkin Lymphoma, Adult
Hodgkin Lymphoma
Drug: MT-601

Phase 1

Marker Therapeutics

Nashville, Tennessee, United States and 6 other locations

patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.ARV-3...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1

Arvinas
Arvinas

Nashville, Tennessee, United States and 7 other locations

Locations recently updated

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Nashville, Tennessee, United States and 66 other locations

A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma...

Enrolling
Diffuse Large B Cell Lymphoma (DLBCL)
Biological: bbT369

Phase 1, Phase 2

2seventy bio

Nashville, Tennessee, United States and 3 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: brentuximab vedotin
Drug: bleomycin

Phase 3

Takeda
Takeda

Nashville, Tennessee, United States and 215 other locations

Locations recently updated

and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Hodgkin Disease
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Nashville, Tennessee, United States and 73 other locations

or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and ...

Active, not recruiting
Lymphoma
Drug: Rituximab
Drug: CC-220

Phase 1

Celgene
Celgene

Nashville, Tennessee, United States and 25 other locations

(firi-cel), a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma...

Enrolling
Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Cancer
Drug: Fludarabine (Conditional therapy)
Drug: firi-cel (Experimental drug)

Phase 2

CARGO Therapeutics

Nashville, Tennessee, United States and 29 other locations

by the intravenous (IV) route to participants with solid tumors or lymphomas.The main goals of this study are to:* Find the recommended dose...

Enrolling
Hodgkin Lymphoma
Follicular Lymphoma
Drug: IMT-009
Combination Product: Fruquintinib

Phase 1, Phase 2

Immunitas Therapeutics

Nashville, Tennessee, United States and 9 other locations

This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combi...

Active, not recruiting
Hodgkin Lymphoma
Drug: doxorubicin
Drug: vinblastine

Phase 2

Seagen
Seagen

Nashville, Tennessee, United States and 75 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems